Business Wire

LABTWIN

14.12.2022 12:01:42 CET | Business Wire | Press release

Share
DSM chooses LabTwin to advance their digitalization strategy in Science & Innovation with the latest voice and AI solutions.

Today, Royal DSM N.V., a global company specializing in health, nutrition, and sustainable living, and LabTwin GmbH, the leading voice and AI-powered digital lab assistant, announce a multi-year license and collaboration agreement. DSM will apply the newly acquired technology in several of their Science & Innovation laboratories globally. Together, we intend to transform how science is performed in research and application labs providing significant value through speeding up innovation cycles at DSM and its partners worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005030/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

DSM partners with LabTwin to empower scientists with the latest voice and AI solutions. (Graphic: Business Wire)

“We are excited to see that LabTwin is already onboarded on multiple of DSM’s R&D premises globally with more than 100 scientists and technicians, and we are looking forward to supporting them further in their digital transformation journey,” said Magdalena Paluch, CEO of LabTwin.

LabTwin’s digital lab assistant enables hands-free data capture through voice notes or connected lab instruments while working at the bench and provides on-the-go access to safety or operational information. LabTwin also talks scientists through protocols and records any deviations or out of specification results. This data is then automatically structured by LabTwin’s deep learning capabilities and enriched with metadata. The digital assistant will form part of DSM’s wider digitalization strategy, including the full integration with DSM’s Electronic Lab Notebooks.

Willi Gottstein, Scientist and Project Manager at DSM explains “LabTwin has already become the digital assistant of many of our experimentalists, leading to better data and result tracking in the lab, FAIR data processing and more efficient reporting in the office. LabTwin significantly lowers the threshold to record observations leading to higher reproducibility of experiments and easier trouble-shooting.”. Hans Roubos, Director Digital Science and Technologies at DSM continues: “LabTwin offers us a Siri-like experience for the Lab with many options for further advancing our lab operations, from guiding our scientists through laboratory protocols to interacting with labware and storing data and observations in a smart, hands-free way”.

Both DSM and LabTwin shall provide more details on this exciting collaboration in the coming year.

Watch this short product tour video to learn more about LabTwin or follow us on LinkedIn.

LabTwin
LabTwin is creating the next generation of digital lab tools for smart labs, starting with the world's first voice-activated lab assistant. With LabTwin, scientists can collect data, access information, manage experiments and streamline documentation simply by talking. Using voice recognition and machine learning technology, LabTwin’s smart assistant simplifies data capture, structures valuable information, and provides suggestions to scientists in real-time so they can make more informed data-driven decisions. LabTwin is backed by BCG Digital Ventures and Sartorius. Its voice-powered assistant is used in chemical companies and in 7 of the Top20 Pharma around the world.

https://www.labtwin.com/

DSM – Bright Science. Brighter Living. ™

Royal DSM is a global science-based company active in health & nutrition. DSM is organized in three Business Groups: Food & Beverage, Health Nutrition & Care, and Animal Nutrition & Health. Our long-term success in serving these markets require innovations that are customer-focused, value-adding and differentiating and, at the same time, grounded in market insights as well as best-in-class launch execution capabilities. DSM and its associated companies deliver an annual net sales of about €10 billion with approximately 25,000 employees. More information can be found at www.dsm.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005030/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release

Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release

New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release

More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy​ Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel

Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 11:00:00 CEST | Press release

Acquisition adds widely adopted data observability and reliability capabilities to the Boomi Enterprise Platform, giving enterprises the data quality and governance required to operationalize AI Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key TakeawaysWhat Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-sou

Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 10:00:00 CEST | Press release

Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye